secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K/A
Filed at:   2026-06-26T20:31:01+00:00
Accession:  0001193125-26-285572
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026
--------------------------------------------------------------------------------

- Reverse stock split ratio set at 1-for-20, approved by board after stockholder authorization.
- Certificate of Amendment filed with Delaware; effective 11:59 pm ET June 29.
- Shares trade split-adjusted on Nasdaq starting June 30; new CUSIP 22053A305.
- Outstanding shares reduce from ~19.56M to ~0.98M; fractional shares rounded up.
- All options and warrants proportionally adjusted; Equiniti Trust acts as exchange agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526285572/0001193125-26-285572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526285572/d30985d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-285572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer